Biologics News
EXKIVITY (mobocertinib), First and Only FDA Approved Oral Treatment of EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., NOVEMBER 3, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been
WELIREG (belzutifan), FDA Approved, Available at Biologics by McKesson
CARY, N.C., August 20, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been
REZUROCK™ (belumosudil) Tablets, FDA Approved for Treatment of Chronic Graft-Versus-Host Disease, Available at Biologics by McKesson
CARY, N.C., JULY 30, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, today announced
LUMAKRAS (sotorasib), FDA Approved for Treatment of KRAS G12C-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., June 11, 2021 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas,
NULIBRY (fosdenopterin), First and Only FDA-Approved Therapy to Reduce the Risk of Mortality in Patients with Molybdenum Cofactor Deficiency Type A, Available Exclusively at Biologics by McKesson
CARY, N.C., April 19, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected
FOTIVDA (tivozanib), FDA Approved for Treatment of Relapsed/Refractory Advanced Renal Cell Carcinoma, Available at Biologics by McKesson
CARY, N.C., March 11, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected